Reviva shareholders approve increase in authorized common stock from 115M to 315M; all director nominees elected.

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Authorized common shares increased to 315M from 115M, effective December 10, 2024.
All five director nominees (Bhat, Saxena, Margolin, Patel, Funtleyder) elected.
Ratification of Moss Adams as auditor approved with 20.8M for, 1.7M against.
Advisory say-on-pay approved (6.7M for); board set future advisory votes annually.
Adjournment proposal not needed as share increase vote had sufficient votes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC.: Increased authorized common stock from 115,000,000 to 315,000,000 (effective 2024-12-10).

Change: charter amendment
Effective: 2024-12-10

Exact text from the filing

On December 10, 2024, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-037373

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.